FinnCap Reiterates “Corporate” Rating for Allergy Therapeutics (LON:AGY)


Allergy Therapeutics (LON:AGY)‘s stock had its “corporate” rating reissued by equities research analysts at FinnCap in a research note issued to investors on Thursday, January 16th, ThisIsMoney.Co.Uk reports.

LON:AGY traded up GBX 0.25 ($0.00) during mid-day trading on Thursday, reaching GBX 11.25 ($0.15). The stock had a trading volume of 224,760 shares, compared to its average volume of 167,682. The business has a 50 day simple moving average of GBX 10.90 and a 200 day simple moving average of GBX 11.44. Allergy Therapeutics has a twelve month low of GBX 8 ($0.11) and a twelve month high of GBX 15.70 ($0.21). The company has a debt-to-equity ratio of 6.49, a quick ratio of 2.13 and a current ratio of 2.77. The firm has a market capitalization of $71.57 million and a price-to-earnings ratio of 22.50.

Allergy Therapeutics Company Profile

Allergy Therapeutics plc engages in the research and development of allergy treatments. It sells injectable and sublingual allergen-specific immunotherapies; and offers prescription for the treatment of pollen-related allergies, particularly to grasses, weeds, and trees. The company’s products include Pollinex, Pollinex Quattro, Oralvac, Acarovac Plus, and Venomil.

Featured Story: Learning About the VIX – Volatility Index

Receive News & Ratings for Allergy Therapeutics Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Allergy Therapeutics and related companies with’s FREE daily email newsletter.

Source link


Please enter your comment!
Please enter your name here